Abstract
Background
We tested the hypothesis that combinations and total daily doses of psychotropics for hospitalized patients diagnosed with major psychiatric disorders are rising.
Methods
We evaluated McLean Hospital records of 481 consecutive inpatients with DSM‐IV schizophrenia, schizoaffective, or bipolar disorders in 2004 (n = 278) or 2009 (n = 203) to compare characteristics and treatments.
Results
In 2009, Clinical Global Impression (CGI)‐severity scores were 6% lower at intake and improved 1.7 times more than in 2004, as hospitalization‐length decreased by 12%. Polytherapy (≥ 2 psychotropics) increased in 2009 (affective or schizoaffective disorders > schizophrenia). Total psychotropics/patient (3.1–3.2) remained stable but mood‐stabilizers/patient increased markedly and antipsychotics/patient decreased somewhat in 2009. Antipsychotic‐choice (2009) ranked: quetiapine, aripiprazole, risperidone, and others; mood‐stabilizers ranked: lamotrigine, valproate, lithium, and others (1/4 off‐label). In 2009, final total antipsychotic doses (mg/day) increased by 97%, and mood‐stabilizers by 75%. Adverse‐effect rates fell by half. Factors differing independently for 2009 versus 2004 ranked: (a) more CGI improvement, (b) more mood‐stabilizers/patient, (c) lower admission CGI scores, and (c) higher total antipsychotic dose.
Comment
Combinations and doses of antipsychotic and mood‐stabilizing drugs for inpatients increased markedly (2004 vs. 2009) without consistent correspondence of agents/person and doses, without apparent increase in major adverse effects, and with possibly superior clinical improvement. Copyright © 2010 John Wiley & Sons, Ltd.